Synairgen (LON:SNG) Stock Price Down 0.9% – Here’s What Happened

Shares of Synairgen plc (LON:SNG) dropped 0.9% during trading on Wednesday . The company traded as low as GBX 2.01 ($0.03) and last traded at GBX 2.23 ($0.03). Approximately 81,096 shares were traded during trading, a decline of 87% from the average daily volume of 620,372 shares. The stock had previously closed at GBX 2.25 ($0.03).

Synairgen Trading Down 10.2 %

The business’s 50 day moving average price is GBX 3.98 and its two-hundred day moving average price is GBX 4.12. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.35 and a current ratio of 6.77. The company has a market capitalization of £4.07 million, a price-to-earnings ratio of -67.33 and a beta of -2.23.

About Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).